Nonlinear relationship between plasma and red blood cell pharmacokinetics of chlorthalidone in man

  • Harry L. J. Fleuren
  • Jacques M. van Rossum


Plasma concentrations, red blood cell concentrations, and urinary excretion of chlorthalidone were measured after oral administration of single doses of 100 or 200 mg to ten human subjects. The decay of red blood cell concentrations showed a much longer elimination half-life than the terminal plasma decay curve. The in vitrodistribution of chlorthalidone between plasma and erythrocytes was similar to the in vivodistribution curve obtained from patients who were in a steady-state concentration range. A pharmacokinetic model was developed including nonlinear binding of chlorthalidone by the red blood cells, which in detail accounted for the observed time courses of drug in plasma and erythrocytes simultaneously.

Key words

chlorthalidone pharmacokinetics in man oral administration plasma concentrations red blood cell concentrations nonlinear distribution pharmacokinetic model 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    F. H. Dost.Der Blutspiegel, Thieme, Leipzig, 1953.Google Scholar
  2. 2.
    M. Gibaldi and D. Perrier.Pharmacokinetics, Dekker, New York, 1975.Google Scholar
  3. 3.
    R. E. Notari.Biopharmaceutics and Pharmacokinetics, 2nd ed., Dekker, New York, 1975.Google Scholar
  4. 4.
    J. M. van Rossum. Significance of pharmacokinetics for drug design and the planning of dosage regimens. In E. J. Ariëns (ed.),Drug Design, Vol. I, Academic Press, New York, 1971, pp. 469–521.Google Scholar
  5. 5.
    B. Beermann, K. Hellström, B. Lindström, and A. Rosen. Binding-site interaction of chlorthalidone and acetazolamide, two drugs transported by red blood cells.Clin. Pharmacol. Ther. 17:424–432 (1975).PubMedGoogle Scholar
  6. 6.
    H. L. J. Fleuren and J. M. van Rossum. Pharmacokinetics of chlorthalidone in man.Pharm. Wkbl. 110:1262–1264 (1975).Google Scholar
  7. 7.
    P. Collste, M. Garle, M. D. Rawlins, and F. Sjöqvist. Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses.Eur. J, Pharmacol. 9:319–325 (1976).CrossRefGoogle Scholar
  8. 8.
    D. Dieterle, J. Wagner, and J. W. Faigle. Binding of chlorthalidone (HygrotonR) to blood components in man.Eur. J. Clin. Pharmacol. 10:37–42 (1976).CrossRefGoogle Scholar
  9. 9.
    H. L. J. Fleuren and J. M. van Rossum. Determination of chlorthalidone in plasma, urine and red blood cells by gaschromatography with nitrogen detection. Submitted (1977).Google Scholar
  10. 10.
    K. Diem and C. Lentner.Wissenschaftliche Tabellen, 7th ed., J. R. Geigy S.A., Basel, 1968, pp. 550–552.Google Scholar
  11. 11.
    J. C. Wagner.Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton Ill., 1971, pp. 302–317.Google Scholar
  12. 12.
    G. Beisenherz, F. W. Koss, L. Klatt, and B. Binder. Distribution of radioactivity in the tissues and excretory products of rats and rabbits following administration of C14-Hygroton.Arch. Int. Pharmacodyn. 161:76–93 (1966).PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1977

Authors and Affiliations

  • Harry L. J. Fleuren
    • 1
  • Jacques M. van Rossum
    • 1
  1. 1.Department of PharmacologyUniversity of NijmeganNijmegenThe Netherlands

Personalised recommendations